Pandemic Influenza Vaccine H5n1 Astrazeneca (A/Vietnam/1203/2004 (H5n1) Strain (A/Vietnam/1203/2004, Medi 0141000136))

The A/Vietnam/1203/2004 strain is an inactivated viral antigen that triggers the immune system to generate antibodies against the H5N1 hemagglutinin protein. These antibodies recognize the virus on future exposure, neutralizing it and providing active immunity.

The specific dosing regimen, including the number of doses and interval between administrations, is determined by the prescribing healthcare professional based on regulatory guidance, patient age, health status, and the epidemiological context.

Safety data in pregnancy and lactation are limited. The vaccine should be administered to pregnant or breastfeeding women only when the potential benefits justify any uncertain risks, and after a risk‑benefit assessment by the treating clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and necessary import documentation.

This vaccine uses the A/Vietnam/1203/2004 strain delivered via the nasal route, whereas some alternatives are injectable and may use different H5N1 strains. Efficacy, safety profile, and administration method vary, so clinicians should consider strain match, delivery route, and local regulatory approvals when selecting a product.

The vaccine must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and handling is essential to preserve potency.

Pandemic Influenza Vaccine H5N1 Astrazeneca is administered intranasally. The prescribed dose is sprayed into each nostril using the supplied delivery device, following aseptic technique and the prescriber's instructions.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and significant respiratory distress. Patients should be observed for immediate hypersensitivity signs and instructed to seek medical attention promptly if severe symptoms develop.

Individuals with a known hypersensitivity to any component of the vaccine, including the viral strain or excipients, should not be vaccinated. Additionally, persons who have experienced a severe allergic reaction to a previous dose of an H5N1 vaccine should avoid further administration.